Skip to content

Cancer Diagnoses From Exhaled Breath With Na-nose

Diagnosing Cancers From Healthy From Human Exhaled Breath With Na-nose

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03967652
Enrollment
10000
Registered
2019-05-30
Start date
2019-07-01
Completion date
2022-12-31
Last updated
2019-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Diagnoses Disease, Volatile Organic Compounds

Keywords

Volatile organic chemicals, Cancer, Diagnose Disease, Na-nose, breath diagnoses

Brief summary

Early diagnoses of malignant tumors are pivotal for improving their prognoses. The Exhaled Breath is made up of oxygen, carbon dioxide, nitrogen, water, inert gases and volatile organic compounds (VOCs). Theoretically, the concentration of VOCs in exhalation produced by metabolism in human body is only about nmol/L-pmol/L, which can significantly increase under certain pathological conditions. A series of studies of VOCs diagnosing solid tumors the investigators had been conducted in the past decade. It was found that VOCs in exhaled breath can not only distinguish different types of tumors, but also can make a clear distinction between different stages. Our long-term collaborator, Professor Hossam Haick (Israel Institute of Technology) has developed a nano sensor array, so called Na-nose, which can detect VOCs of the exhaled breath by binding gases to specific chemiresistors coated with gold nanomaterials. The Na-nose has the advantages of low cost, easy to use, good reproducibility and real-time detection for large scale clinical application. This study was to use large clinical samples to validate the diagnostic efficacy of the newly developed Nano-nose( Sniffphone and Breath Screener) for malignant tumors .

Detailed description

Israel Institute of Technology provides two type of Na-nose. One is Breath Screener used for large-scale sampling and feature VOCs extraction to establish database. The other is called Sniff Phone aim at clinical real-time VOCs detection assisted by software. About 10,000 patients will participate in the subject of Breath Screener in batches. First, 7000 patients will have a definitive diagnosis and exhaled breath collected. Feature VOCs of specific tumors will be extracted from these samples and employed to build predictive model by using discriminant factor analysis (DFA). After the predictive model had been completed, 3000 definitively diagnosed patients will participate in validating the specificity and sensitivity of the prediction model. With the assistance of Breath Screener clinical database and software services, Sniff Phone is more suitable for clinical real-time detection for its small and convenient design characteristics. At last, Breath Screener and Sniff Phone will continue enriching databases and improve diagnosis efficacy in their clinical applications.

Interventions

DIAGNOSTIC_TESTNanomaterial-based sensors

Chemical sensors based on Monolayer-Capped Metallic Nanoparticles (MCMNPs) can recognize and classify exhaled breath by special recognition algorithm, which achieves the purpose of disease diagnosis.

Sponsors

Technion, Israel Institute of Technology
CollaboratorOTHER
Anhui Medical University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* 18-75 years * Cancer/benign disease having been diagnosed by pathology * ECOG \< 2

Exclusion criteria

* Concomitant malignancies other than one malignant tumor * Diabetes, Fatty liver * Autoimmune disease * Ventilation and transaired function obstacle

Design outcomes

Primary

MeasureTime frameDescription
Build predictive diagnosis databaseFrom July 01,2019 to December 31,2021First, feature VOCs of specific tumors will be extracted from part of collected samples and employed to build predictive model. After the predictive model had been completed, number of definitively diagnosed patients will participate in validating the specificity and sensitivity of the prediction model.

Secondary

MeasureTime frameDescription
Associated feature exhaled breath with differentially expressed genesFrom Juan 01,2022 to December 31,2022Integrate the correlation and relevance between the exhaled samples and the differentially expressed genes in the cancer group and the benign / normal control group to explore the mechanism of feature VOCs' production.

Contacts

Primary ContactBao Chuyang, MD
des_mond@outlook.com+86 18555039598
Backup ContactHu Liu, MD
drliuhu@yahoo.com+86 13866175691

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026